{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:06:11Z","timestamp":1771553171331,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Background and Objective:<\/jats:title>\n            <jats:p>Immune-mediated diarrhea and colitis (IMDC) is a common adverse event in cancer patients receiving immune checkpoint inhibitors (ICIs). Gastrointestinal (GI) infections can co-occur with IMDC, and its impact on the course and outcome of IMDC remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>We retrospectively reviewed cancer patients who received ICIs and developed IMDC between January 2015 and September 2019. GI multiplex panel is used to assess GI infection. The study group included patients with positive infection except those who are only positive for <jats:italic toggle=\"yes\">Clostridioides difficile<\/jats:italic> or cytomegalovirus. The control group is IMDC patients with negative infection using frequency matching. Patients\u2019 disease course and outcome were compared between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 72 patients with IMDC were included: 22 in the study group and 50 as control. <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic> of different pathotypes was observed in 17 patients. Five patients had viral infections, for example, adenovirus, norovirus, and sapovirus. Patients with GI infections more frequently had grade 3 or 4 colitis (43% vs. 18%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.041). Overall, GI infections were not associated with different risks of IMDC recurrence or overall survival. Antibiotics treatment did not affect the requirement for infliximab or vedolizumab but relate to a higher risk of IMDC recurrence (50.0% vs. 0.0%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.015).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In our study, concomitant GI infections are associated with more severe symptoms in IMDC patients. Antimicrobial treatment did not circumvent the need for immunosuppressive therapy for IMDC or improve the clinical outcome. Concomitant GI infection was not associated with a higher risk of IMDC recurrence or poor overall survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000841","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:21Z","timestamp":1623283221000},"page":"402-408","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of Immune Checkpoint Inhibitor\u2013related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections"],"prefix":"10.1097","volume":"44","author":[{"given":"Weijie","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province"},{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zimu","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Joseph Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamzah","family":"Abu-Sbeih","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Missouri, Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Rice University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangwen","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, People\u2019s Republic of China"},{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Charabaty","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sibley Memorial Hospital, Johns Hopkins University, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo C.","family":"Okhuysen","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Infection Control, and Employee Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"McQuade","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[{"name":"Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha S.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"R291","DOI":"10.1186\/cc2893","article-title":"Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care","volume":"8","author":"Williams","year":"2004","journal-title":"Crit Care"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/cid\/cix669","article-title":"2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea","volume":"65","author":"Shane","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/01.meg.0000131040.38607.09","article-title":"Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool","volume":"16","author":"Mylonaki","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/MPG.0b013e31818255cc","article-title":"Gastrointestinal norovirus infection associated with exacerbation of inflammatory bowel disease","volume":"48","author":"Khan","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3892\/etm.2012.718","article-title":"Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease","volume":"4","author":"Wang","year":"2012","journal-title":"Exp Ther Med"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3748\/wjg.v22.i3.1078","article-title":"Role of antibiotics for treatment of inflammatory bowel disease","volume":"22","author":"Nitzan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.aad9358","article-title":"Antibiotic use and its consequences for the normal microbiome","volume":"352","author":"Blaser","year":"2016","journal-title":"Science"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s40425-019-0714-x","article-title":"Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1084\/jem.186.1.65","article-title":"Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help","volume":"186","author":"Bennett","year":"1997","journal-title":"J Exp Med"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"R17-20250527","first-page":"646","article-title":"Use and interpretation of enteropathogen multiplex nucleic acid amplification tests in patients with suspected infectious diarrhea","volume":"14","author":"Yalamanchili","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:08:21Z","timestamp":1748365701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000841","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,9]]}}}